US commissioner renews call for strengthening regulatory science
This article was originally published in Scrip
Executive Summary
US Food and Drug Administration commissioner Margaret Hamburg has renewed her call for the agency and for regulators worldwide to invest in and strengthen the field of regulatory science. Neena Brizmohun reports from the 46th Annual Meeting of the Drug Information Association in Washington, DC, taking place from 13-17 June.
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Outlook Turns To Marketing Strategy After Scoring EU First For Ophthalmic Bevacizumab
Outlook Therapeutics’ intravitreally injected Lytenava has won the thumbs up from the European Medicines Agency. The company is assessing both direct commercialization of the product and partnering in Europe on a country-by-country basis.
EU CHMP Opinions And MAA Updates
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.